Atypical parathyroid adenoma with clinically aggressive course of hyperparathyroidism: clinical case report

Primary hyperparathyroidism is common clinical endocrine disorder with a prevalence between 1–2%. Solitary parathyroid adenomas account from 80 to 85% of cases of PHPT, hyperplasia and multiple adenomas is up to 15%, parathyroid carcinoma is a very rare cause of PHPT, accounting for about a 1% of cases. Clinically aggressive and atypical adenomas should be separately noted because of severe clinical course and life-threatening hypercalcemia, high morbidity and mortality, unknown malignant potential. No definite criteria are considered to be present to distinguish preoperatively atypical adenoma from parathyroid typical adenoma or carcinoma. The clinical course of the disease remains the only tool that allows to suspect an aggressive tumor on the preoperative stage. We present the clinical case of a 61-year-old female patient with a clinically “aggressive” course of PHPT and severe metabolic disturbances of bone tissue due to the atypical adenoma of the parathyroid gland.

1. Newey PJ, Nesbit MA, Rimmer AJ, et al. Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. J Clin Endocrinol Metab. 2012;97(10):E1995-2005. doi: 10.1210/jc.2012-2303.

2. Yu W, McPherson JR, Stevenson M, et al. Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. J Clin Endocrinol Metab. 2015;100(2):E360-364. doi: 10.1210/jc.2014-3238.

3. Cakir B, Polat SB, Kilic M, et al. Evaluation of preoperative ultrasonographic and biochemical features of patients with aggressive parathyroid disease: is there a reliable predictive marker? Arch Endocrinol Metab. 2016;60(6):537-544. doi: 10.1590/2359-39970000002244.

4. Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician. 2003;67(9):1959-1966.

5. Marcocci C, Cetani F, Rubin MR, et al. Parathyroid carcinoma. J Bone Miner Res. 2008;23(12):1869-1880. doi: 10.1359/jbmr.081018.

6. Almquist M, Bergenfelz A, Martensson H, et al. Changing biochemical presentation of primary hyperparathyroidism. Langenbecks Arch Surg. 2010;395(7):925-928. doi: 10.1007/s00423-010-0675-5.

7. Bergson EJ, Sznyter LA, Dubner S, et al. Sestamibi scans and intraoperative parathyroid hormone measurement in the treatment of primary hyperparathyroidism. Arch Otolaryngol Head Neck Surg. 2004;130(1):87-91. doi: 10.1001/archotol.130.1.87.

8. Airaghi L, Pisano G, Pulixi E, et al. Unusual presentation in a case of primary hyperparathyroidism. J Res Med Sci. 2011;16(8):1078-1081.

9. Caldarella C, Treglia G, Isgro MA, Giordano A. Diagnostic performance of positron emission tomography using (1)(1)C-methionine in patients with suspected parathyroid adenoma: a meta-analysis. Endocrine. 2013;43(1):78-83. doi: 10.1007/s12020-012-9746-4.

10. Givi B, Shah JP. Parathyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22(6):498-507. doi: 10.1016/j.clon.2010.04.007.

11. Tan MH, Morrison C, Wang P, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res. 2004;10(19):6629-6637. doi: 10.1158/1078-0432.CCR-04-0493.

12. Haven CJ, van Puijenbroek M, Karperien M, et al. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol. 2004;202(1):86-94. doi: 10.1002/path.1489.

13. Gospodarowicz MK, Brierley JD, Wittekind C (ed.). TNM classification of malignant tumours. John Wiley & Sons, 2017. doi: 10.1016/S1470-2045(17)30438-2.

14. Bondeson L, Grimelius L, Delellis RA. World Health Organisation Classification of tumours, pathology and genetics: tumour of endocrine organs. Lyon: IARC Press; 2004.

15. Duan K, Mete O. Parathyroid carcinoma: diagnosis and clinical implications. Turk Patoloji Derg. 2015;31 Suppl 1:80-97. doi: 10.5146/tjpath.2015.01316.

16. Mackenzie-Feder J, Sirrs S, Anderson D, et al. Primary hyperparathyroidism: an overview. Int J Endocrinol. 2011; 2011:251410. doi: 10.1155/2011/251410.

17. Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007;110(2):255-264. doi: 10.1002/cncr.22790.

18. LiVolsi VA, Montone KT, Baloch ZN. Parathyroid: the pathology of hyperparathyroidism. Surg Pathol Clin. 2014;7(4): 515-531. doi: 10.1016/j.path.2014.08.004.

19. Callender GG, Udelsman R. Surgery for primary hyperparathyroidism. Cancer. 2014;120(23):3602-3616. doi: 10.1002/cncr.28891.